Neutropenia associated with xanomeline‐trospium

Xanomeline‐trospium (Cobenfy®) is a new antipsychotic with a mechanism of action different from that of currently available typical and atypical antipsychotics. Instead of blocking dopamine D‐2 receptors, xanomeline‐trospium acts as an agonist at muscarinic M1/M4 receptors, resulting in decreased dopamine release in psychosis‐implicated regions of the brain. The trospium component of the combination serves as a selective muscarinic antagonist in the periphery, thereby alleviating xanomeline‐mediated cholinergic effects.